Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Nexalin Technology, Inc.

Get SEC filing alerts via email and in your feed for Nexalin Technology, Inc.

NXL NXLIW

Nexalin Technology, Inc.

About Nexalin Technology, Inc.

Nexalin Technology develops non-invasive neurostimulation devices targeting mental health conditions such as anxiety, insomnia, depression, and PTSD. Utilizing proprietary waveform technology, the company offers cranial electrotherapy stimulation (CES) devices for clinical and home use. Its business includes device development, clinical trials, regulatory approval, and a virtual clinic platform to deliver cost-effective, drug-free treatments monitored by healthcare providers worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Nexalin Technology, Inc.

1
1
Nexalin Technology, Inc. Nexalin Technology Reports $8.22 Million Net Loss and 79% Revenue Growth for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

2
1
Nexalin Technology, Inc. Nexalin Technology Reports 50% Revenue Decline and Increased Operating Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Nexalin Technology, Inc. Nexalin Technology Reports 163% Revenue Increase but Faces $1.58M Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Nexalin Technology, Inc. Nexalin Technology Reports $7.6 Million Comprehensive Loss, Revenue Rises 52% to $168,721

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Nexalin Technology, Inc. Nexalin Technology Reports 57% Revenue Growth, Net Loss Increase in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments